Abid Syed Mobasher Ali, Younus Hafiza Amna, Al-Rashida Mariya, Arshad Zunaira, Maryum Tooba, Gilani Mazhar Amjad, Alharthi Abdulrahman I, Iqbal Jamshed
Centre for Advanced Drug Research, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan.
Department of Chemistry, Forman Christian College (A Chartered University), Ferozepur Road, Lahore 54600, Pakistan.
Bioorg Chem. 2017 Dec;75:291-302. doi: 10.1016/j.bioorg.2017.10.001. Epub 2017 Oct 4.
A series of sulfonyl hydrazones derived from 3-formylchromone was synthesized and discovered to be effective, non-selective inhibitors of monoamine oxidases (MAO-A and MAO-B). The compounds are easily (synthetically) accessible in high yields, by simple condensation of 4-methylbenzenesulfonohydrazide with different (un)substituted 3-formylchromones. All compounds had IC values in lower micro-molar range (IC = 0.33-7.14 μM for MAO-A, and 1.12-3.56 μM for MAO-B). The most active MAO-B inhibitor was N'-[(E)-(6-fluoro-4-oxo-4H-chromen-3-yl)methylidene]-4-methylbenzenesulfonohydrazide (3e) with IC value of 1.12 ± 0.02 μM, and N'-[(E)-(6-chloro-4-oxo-4H-chromen-3-yl)methylidene]-4-methylbenzenesulfonohydrazide (3f) was the most active MAO-A inhibitor with IC value of 0.33 ± 0.01 μM. From enzyme kinetic studies, the mode of inhibition against MAO-B was found to be competitive, whereas against MAO-A, it was found to be non-competitive. Molecular docking studies indicated a new binding pocket for non-competitive MAO-A inhibitors. The activity of these compounds is optimally combined with highly favorable ADME profile with predicted good oral bioavailability.
合成了一系列由3-甲酰基色酮衍生的磺酰腙,发现它们是单胺氧化酶(MAO-A和MAO-B)的有效非选择性抑制剂。通过4-甲基苯磺酰肼与不同(未)取代的3-甲酰基色酮的简单缩合反应,这些化合物能够以高产率轻松(通过合成方法)获得。所有化合物的IC值都在较低的微摩尔范围内(MAO-A的IC = 0.33 - 7.14 μM,MAO-B的IC = 1.12 - 3.56 μM)。活性最高的MAO-B抑制剂是N'-[(E)-(6-氟-4-氧代-4H-色烯-3-基)亚甲基]-4-甲基苯磺酰肼(3e),其IC值为1.12 ± 0.02 μM,而N'-[(E)-(6-氯-4-氧代-4H-色烯-3-基)亚甲基]-4-甲基苯磺酰肼(3f)是活性最高的MAO-A抑制剂,IC值为0.33 ± 0.01 μM。通过酶动力学研究发现,对MAO-B的抑制模式是竞争性的,而对MAO-A的抑制模式是非竞争性的。分子对接研究表明存在一个新的非竞争性MAO-A抑制剂结合口袋。这些化合物的活性与高度有利的ADME特性得到了最佳结合,预测具有良好的口服生物利用度。